P2Y Purinergic Receptor Neurons are neurons expressing the P2Y receptor, a member of the Purinergic receptor family. These receptor neurons play crucial roles in modulatory signaling, glial-neuron communication and are implicated in various neurological and neurodegenerative conditions.
| Property |
Value |
| Receptor Type |
P2Y |
| Family |
Purinergic |
| Signaling Mechanism |
G protein-coupled, slower metabotropic signaling |
| Primary Location |
Hippocampus, cortex, astrocytes |
P2Y Purinergic Receptor Neurons are involved in Modulatory signaling, glial-neuron communication. These neurons express the P2Y receptor which g protein-coupled, slower metabotropic signaling. The receptor's location in hippocampus, cortex, astrocytes allows it to modulate neurotransmission and cellular signaling in key brain regions.
The P2Y receptor signals through g protein-coupled, slower metabotropic signaling. This mechanism allows rapid or modulatory responses depending on the cellular context and co-expression of other receptors.
Neuroinflammation, stroke, neurodegenerative disease. Understanding the role of these receptor neurons provides insight into potential therapeutic targets for these conditions.
The P2Y receptor is a target for drug development in:
- Neurological disorders
- Neuropsychiatric conditions
- Neurodegenerative diseases
- G protein-coupled receptor signaling in neurons
- Purinergic receptor pharmacology
- Receptor neurons in neurodegenerative disease
The P2Y receptor family includes multiple subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14), each with distinct pharmacological profiles and tissue distributions. In the brain, P2Y1, P2Y2, P2Y12, and P2Y14 are the most abundantly expressed.
- ADP as primary agonist
- Gi/o protein-coupled
- Expressed in hippocampus and cortex
- Modulates synaptic plasticity
- ATP and UTP as agonists
- Gq protein-coupled
- Involved in glial communication
- upregulated in neuroinflammation
- ADP as primary agonist
- Gi/o protein-coupled
- Expressed in platelets and microglia
- Target of clopidogrel (antiplatelet drug)
P2Y receptors play complex roles in neuroprotection:
- ATP release acts as a danger signal
- Microglial surveillance modulated by P2Y receptors
- Astrocyte function regulated through P2Y signaling
- Neurogenesis influenced by purinergic signaling
- Primary neuronal cultures
- Astrocyte-microglia co-cultures
- Organotypic brain slices
- P2Y knockout mice
- P2Y agonist/antagonist administration
- K+ depletion models
P2Y receptor modulation shows promise for:
- Stroke intervention (P2Y12 antagonists)
- Neuroinflammation (P2Y6 antagonists)
- Cognitive enhancement (P2Y1 agonists)
- Demyelinating diseases (P2Y11 modulation)
- Burnstock et al., Purinergic signalling (2013)
- Illes et al., P2Y receptors in the central nervous system (2020)
- Jacobson et al., P2Y and adenosine receptors (2019)
P2Y receptors primarily couple to Gi/o or Gq protein subtypes, leading to distinct downstream signaling cascades:
- Gi/o coupling: Inhibits adenylate cyclase, reduces cAMP levels
- Gq coupling: Activates phospholipase C, increases IP3 and DAG
- MAPK activation (ERK1/2, p38, JNK)
- Calcium mobilization from intracellular stores
- PI3K/Akt survival pathway modulation
- NF-κB transcription factor activation
- P2Y1R: Altered in hippocampus, affects amyloid-beta toxicity
- P2Y2R: Upregulated in reactive astrocytes
- P2Y12R: Microglial activation marker
- P2Y12R: Upregulated in substantia nigra
- P2Y6R: Involved in microglial phagocytosis
- P2Y2R: Neuroprotective in dopaminergic neurons
¶ Stroke and Ischemia
- ATP release during ischemia activates P2X and P2Y receptors
- P2Y12R antagonists show neuroprotective effects
- P2Y1R activation reduces infarct size
- P2Y12R: Demyelination marker
- P2Y11R: Oligodendrocyte differentiation
- Purinergic modulation as therapeutic target
- ADP (P2Y1, P2Y12, P2Y13)
- UTP (P2Y2, P2Y4, P2Y6)
- UDP (P2Y6)
- MRS2365 (P2Y1 selective)
- MRS2690 (P2Y2 selective)
- MRS2179 (P2Y1)
- AR-C66096 (P2Y12)
- MRS2578 (P2Y6)
- Brilliant Blue G (P2X7, also affects P2Y)
- Blood-brain barrier penetration: Developing CNS-active P2Y ligands
- Subtype selectivity: Creating more selective pharmacological tools
- Gene therapy: Targeting specific P2Y subtypes
- Biomarkers: P2Y expression as disease markers